Dr. Anibal Drelichman, MD

Dr. Drelichman practices at Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Drelichman's NPI, 1740222447, was assigned on June 10, 2006. Dr. Drelichman holds Michigan license AD036112.

Dr. Drelichman's primary practice is Henry Ford St. John Hospital, at 22101 Moross Rd, Detroit, MI 48236 in Wayne County. The practice phone is (313) 343-4000.

Dr. Drelichman's primary practice is Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Drelichman is also affiliated with Henry Ford Rochester Hospital. The medical group on file is Newland Medical Associates. Dmand AI also links Dr. Drelichman to 2 more group practices and clinics, 2 medical groups and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Drelichman practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Drelichman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Drelichman is licensed in Michigan.

CMS data shows 3,684 Medicare services from Dr. Drelichman across 7 procedure codes in 2024, for 190 Medicare patients. Medicare paid $89,499 for them. Every service was in an office.

CMS counts 190 Medicare patients who saw Dr. Drelichman in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have high blood pressure, and 72% have high cholesterol. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Drelichman's median patient age at 71, with 71% women.

In 2024, Dr. Drelichman wrote 135 Medicare Part D claims for 56 patients. 75% of them were for generic drugs. CMS names the drug for 49 of them, across 3 drugs with 11 or more claims each, at $13,288 in total drug cost. In 2021, CMS named 186 claims across 10 drugs.

Dr. Drelichman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Drelichman to 8 clinical trials, 7 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Brain Neoplasms and Breast Neoplasms, Male. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 567 general payments to Dr. Drelichman from 58 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 46% of the total. Novartis Pharmaceuticals Corporation paid the most, $8,910.